TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study

  • End date
    Sep 28, 2028
  • participants needed
  • sponsor
    Theravance Biopharma
Updated on 28 January 2021
Theravance Biopharma Call Center
Primary Contact
Theravance Biopharma Investigational Site (3.8 mi away) Contact
+158 other location


A 3-Year Multi-Center, Long-Term Safety (LTS) Study to Evaluate the Safety and Tolerability of TD-1473 in Subjects with Ulcerative Colitis who have participated in the Maintenance Study of Protocol 0157


This is a multi-center, long-term safety study to evaluate the safety and tolerability of TD-1473 for up to 156 weeks (3 years) + 4 week follow-up in subjects with moderate to severe UC exiting the preceding Maintenance Study of Protocol 0157 (NCT03758443).

Condition Ulcerative Colitis, Ulcerative Colitis (Pediatric)
Treatment TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C
Clinical Study IdentifierNCT03920254
SponsorTheravance Biopharma
Last Modified on28 January 2021


Yes No Not Sure

Inclusion Criteria

To be eligible for the study, subjects are required to enter the LTS Study
within 14 days of exiting the Maintenance Study of Protocol 0157 and must meet
all the following criteria
Capable of providing informed consent, which must be obtained prior to any study related procedures
One of the following
Those who demonstrated persistent loss of response (no improvement 8 weeks after meeting loss of response criteria) OR
Two Clinical Flares after an episode of loss of response during the Maintenance Study OR
Those who have completed the Maintenance Study and confirmation of clinical remission status results are available
During the study and for 7 days after receiving the last dose of the study drug, females of childbearing potential or men capable of fathering children must agree to use highly effective birth control measures (failure rate <1% when used consistently and correctly)) or agree to abstain from sexual intercourse. Females of childbearing potential must test negative for pregnancy at Day 1
All male subjects must agree to refrain from semen donation during the study and for 7 days after the last dose of study drug
Must be able and willing to adhere to the study visit schedule and comply with other study requirements

Exclusion Criteria

Has symptoms suggestive of fulminant colitis, megacolon or intestinal perforation
Likely to require surgery for UC or other major surgeries
Has previously received / is currently receiving prohibited medications
Has been diagnosed during Protocol 0157 with Crohn's disease, other colitis conditions or the subject has a current or past diagnosis of a fistula or abdominal abscess
Has endoscopic findings during Protocol 0157 of colitis-associated colonic dysplasia (with the exception of subjects with non-colitis associated spontaneous adenomas that have been completely resected)
Has clinically significant abnormalities in laboratory evaluations
Additional exclusion criteria apply
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note